Laszlo’s current research focuses on the development of antimicrobial peptides to resistant infections as well as agonists and antagonists to adipokine receptors. His first-of-kind and optimized peptide analogs show promising preclinical advantages over conventional therapy against not only bacterial infections, but also metabolic and cardiovascular diseases, certain cancer types and arthritis forms. In all these efforts Laszlo frequently interacts with Australian research groups. Currently Laszlo serves as Councilor for the American Peptide Society and as Regional Editor for Protein and Peptide Letters. His research papers have been cited >10000 times.